Welcome to REVIVE
Advancing care to save lives affected by Advanced HIV Disease
REVIVE is a clinical trial dedicated to reducing mortality and improving care for people with Advanced HIV Disease (AHD).
AHD is a leading cause of death in sub-Saharan Africa and presents significant public health challenges. Severe bacterial infections, which often occur during the critical early period after starting antiretroviral therapy, are a major driver of mortality in people with AHD.
Through innovative research, the REVIVE trial aims to provide the evidence needed to support the use of azithromycin prophylaxis as part of routine HIV care. By tackling a critical cause of early mortality, we aim to save lives and deliver better outcomes for people living with AHD.
Your guide to understanding REVIVE
Find everything you need to stay informed and engaged with the REVIVE trial.
REVIVE in numbers
Total participants randomised
Countries involved
Active clinical sites
Recent randomisations (last 30 days)
Last updated date
2026-08-19
Stay informed with REVIVE webinars and events
Next Steering Committee Meeting
Date: 3 September 2025
Time: 08:00 SAT
Details: 3 September - 6 September
Note: Location: Four Points by Sheraton, Kigali, Rwanda
Optimising Treatment for Drug-Sensitive Pulmonary TB
Speaker: Dr Christine Sekaggya
Date: 22 September 2025
Time: 15:00 SAST
Sepsis in Advanced HIV Disease
Speaker: Prof Nicholas A. Feasey
Date: 19 November 2025
Time: 15:00 SAST
Malaria & HIV In Sub-Saharan Africa (Malaria In The High-Risk Group, Like HIV, And Present On RTS,S, And R21 Vaccinations In Ghana)
Speaker: Dr Daniel Onsong
Date: 25 November 2025
Time: 15:00 SAST
“New interventions that are affordable and safe are urgently needed to reduce the high mortality among people with advanced HIV disease. A successful REVIVE trial will provide definitive evidence for the use of azithromycin prophylaxis in this vulnerable population, saving lives in Africa and beyond.”
Proud partnership by leaders in global health.
The REVIVE Clinical Trial is proudly funded by the Bill & Melinda Gates Foundation, driving innovation and impact in global health research.
